Introduction: This sub-analysis of the A 1 chieve
INTRODUCTION
The main goal of type 2 diabetes mellitus (T2DM) management is to safely improve glycemic control [1] . The joint guidelines of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend maintaining glycated hemoglobin A 1c (HbA 1c ) levels \7.0%
(\53 mmol/mol) for good glycemic control in patients with T2DM [2] . The guidelines also recommend a stepwise pathway for the initiation and subsequent intensification of oral glucose-lowering drugs (OGLDs) and insulin to combat the progressive nature of T2DM [2] . However, despite these recommendations, many T2DM patients continue to experience poor glycemic control in real-life settings [3] .
Weight gain is a common consequence of intensified pharmacological therapy in T2DM [4] . Approximately 80% of patients with T2DM [2]. Insulin is the most effective treatment for T2DM; however, possible weight gain resulting from insulin use is regarded as a major barrier to the initiation of insulin by many patients and physicians alike [5] and may be the cause of delayed insulin initiation in T2DM patients who are already overweight or obese [6] . It is, therefore, important to determine the potential impact of baseline BMI status on T2DM management strategies and patient outcomes in clinical practice. The basal insulin analog, insulin detemir (IDet), is known to be safe and efficacious in the management of T2DM and induces less weight gain compared to treatment with other basal insulins, such as neutral protamine Hagedorn (NPH) insulin and insulin glargine [7] . IDet differs from endogenous insulin in that threonine has been deleted at position B30 and a myristic acid side chain is attached to the lysine residue at position B29 of the insulin molecule [8] . Due to these structural modifications, IDet molecules have a strong tendency to selfassociate and are highly bound to albumin in the subcutaneous depot, resulting in prolonged therapeutic action. A pooled analysis examining data from 900 T2DM patients treated with either IDet or NPH insulin in a basal-bolus regimen by Raslová et al. [9] demonstrated that patients on IDet therapy gained less weight compared to those on NPH insulin and the weight-limiting effect increased with baseline BMI.
The mechanism underlying the low weight gain noted with IDet therapy is currently unconfirmed [10] . It is possible that the low glucose variability associated with IDet therapy minimizes defensive snacking thereby limiting weight gain. It has also been hypothesized that IDet may have a positive effect on satiety signaling in the central nervous system [10] , while another theory proposes that IDet may have a role in suppressing adipogenesis in the peripheral tissues due to its albumin-binding tendencies that promote greater exposure to hepatocytes than to peripheral tissues [10] .
This sub-analysis of the A 1 chieve study [11] aimed to examine the safety and efficacy of IDet therapy in T2DM management in relation to baseline BMI in a heterogeneous cohort of insulin-naïve patients. It is important to explore whether T2DM management practices are affected by baseline BMI status and also to determine whether the weight-limiting effects of IDet therapy in relation to baseline BMI are sustained in real-life clinical practice. Data analysis was performed by Novo Nordisk using SAS (Version 9.1.3).
MATERIALS AND METHODS

RESULTS
Patient Disposition and Baseline Demographics
Overall, 12,078 insulin-naïve patients initiated IDet therapy; however, baseline BMI data was missing for 1,428 patients. Therefore, this subanalysis included 10,650 patients, who initiated IDet therapy. No other insulin therapy was administered during the 24-week study. Patient characteristics for the entire cohort, stratified by baseline BMI intervals, are presented in Table 1 . The mean baseline HbA 1c level was high across all four groups (Table 1) . Over 97.0% of patients initiated IDet therapy to improve glycemic control across all groups.
The most commonly used OGLDs in each group at pre-study (prior to study enrolment), baseline and Week 24 are presented in Table 2 .
At pre-study, baseline and Week 24, a higher proportion of patients with a higher baseline BMI were on more than two OGLDs.
Insulin Dose and Dosing Frequency
The mean total daily insulin dose, dose by body weight and dosing frequency are presented in Table 3 .
At baseline, the mean insulin dose by weight was lowest in Group IV (0.20 ± 0.12 U/kg). At Week 24, the mean insulin dose by weight was observed to be similar across the four groups (Group I, 0.36 ± 0.18 U/kg; Group II, 0.35 ± 0.19 U/kg; Group III, 0.35 ± 0.18 U/kg; Group IV, 0.35 ± 0.18 U/kg), while the total daily insulin dose was noted to increase with increasing BMI (Group I, 21.8 ± 11.4 U/day; Group II, 25.9 ± 14.2 U/day; Group III, 29.9 ± 15.6 U/day; Group IV, 34.8 ± 18.9 U/day).
The majority of patients ([75.0%) in all four groups followed once-daily dosing at baseline and Week 24.
SADRs and Hypoglycemia
A total of 4 SADRs, all considered probably related to IDet therapy, were reported: 1 event of hyperglycemia in Group I, and 2 events of hypoglycemia and 1 event of hyperglycemia in Group II.
In Group I, there was no statistically significant difference in the proportion of patients reporting overall hypoglycemia from the 4 weeks preceding baseline to the 4 weeks preceding the final visit (4.0% vs. 4.4%, Table 4 ). In Group II, a significant decrease was noted in the proportion of patients reporting overall hypoglycemia from the 4 weeks preceding baseline to the 4 weeks preceding the final visit (4.8% vs. 4.0%, p = 0.0335), while in Groups III and IV, significant increases were noted in the proportion of patients reporting overall hypoglycemia from the 4 weeks preceding baseline to the 4 weeks preceding the final visit (3.3% vs. 5.4% and 3.4% vs. 7.0%, respectively, both p\0.001).
During the 4 weeks preceding the final visit, only 1 event of major hypoglycemia was After 24 weeks, a significant increase in body weight was noted in Group I (1.0 ± 3.2 kg), while significant decreases were observed in the remaining three groups (all p\0.001, Table 5 ). Greater weight reductions were observed with high BMI (Group II, -0.3 ± 3.5 kg; Group III, -1.4 ± 4.3 kg; Group IV, -2.2 ± 5.0 kg). The mean SBP improved markedly across all groups (all p\0.001, Table 5 ). The mean total daily IDet dose at baseline and Week 24 is presented in units of U/day and U/kg for each group. Dosing frequency of IDet at baseline and Week 24 is summarized and presented as once daily, twice daily, thrice daily and [thrice daily. As this was a non-interventional study, data collection was based on the number of patients that reported dose details at baseline and Week 24 BMI body mass index a Data are represented as mean ± SD b Data are represented as n (%) 
Lipid Profile
Baseline lipid levels appeared to be similar across the four groups. Significant reductions were noted in total cholesterol, triglyceride and LDL cholesterol levels across all groups from baseline to Week 24 (all p\0.001, Table 6 ).
There was no significant change in HDL All data are mean ± SD or as stated BMI body mass index, FPG fasting plasma glucose, HbA 1c glycated hemoglobin A1c, PPPG postprandial plasma glucose, SBP systolic blood pressure cholesterol in Group I, while significant increases were noted in the remaining three groups (all p\0.001, Table 6 ).
Quality of Life
The mean EQ-5D VAS scores improved significantly from baseline to Week 24 for all groups (Group I, 63. Week 24 2.7 ± 0.8 2.7 ± 0.9 2.7 ± 0.8 2.7 ± 0.8
All data are mean ± SD or as stated. As this was a non-interventional study, data collection was based on the number of patients with lipid measurements at baseline and Week 24 BMI body mass index, HDL high-density lipoprotein, LDL low-density lipoprotein subgroups, stratified by baseline BMI intervals, with only four SADRs reported in the entire cohort of 10,650 patients. Body weight is known to impact the progression of T2DM with weight gain leading to increased insulin resistance [12] . Weight loss is the chief recommendation for overweight and obese patients with T2DM according to the 2013 ADA Standards of Medical Care [13] , and this is also endorsed by the International Diabetes Federation global guidelines for T2DM [14] . Meneghini et al. [1] suggested that T2DM patients with an HbA 1c level close to the ADA target of \7.0% (\53 mmol/mol) might benefit from glucose-lowering therapies that minimize weight gain. However, for patients with very poor glycemic control [HbA 1c levels[8.0% ([64 mmol/mol)], the first priority must be to improve glycemic control, followed by modulating weight gain [15] . At baseline, all patient subgroups had mean ); however, the overall incidence of hypoglycemia at Week 24 remained low (1.59 and 2.36 events per patient-year, respectively). These results are in keeping with the known safety profile of IDet [7] . The incidence of minor and nocturnal hypoglycemic events also remained low at the end of the study, while only 1 event of major hypoglycemia was reported at Week 24 in a patient from Group IV (C35.0 kg/m 2 ).
IDet is known to exert a beneficial effect on weight gain and the findings from this study are in accordance with previously reported results from clinical trials [16, 17] . A modest, OGLD regimens, also indicated that changes in body weight from baseline after initiating IDet treatment were related to baseline BMI [18] . In two clinical trials, patients with higher baseline BMI gained less weight with IDet therapy [16, 19] and this finding was also noted in a subgroup analysis of the large, observational PREDICTIVE study on IDet therapy [20] . High blood pressure and abnormal lipid levels are common co-morbidities in T2DM patients with poor glycemic control [21] . Patients with T2DM often avoid the initiation of insulin due to perceptions that life will become more restricted [23] . 
